A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers

NCT07215923 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Thromboangiitis Obliterans (Buerger's Disease)

Interventions

BIOLOGICAL: ATI-1013 (0.2 g)
BIOLOGICAL: ATI-1013 (0.8 g)
BIOLOGICAL: ATI-1013 (3.2 g)
OTHER: Placebo

Sponsor

Antidote Therapeutics, Inc

Collaborators

[object Object]
[object Object]